MedTrace Logo

Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies

NCT07710781 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-07-20

No results posted yet for this study

Summary

Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.

Conditions

Interventions

OTHER

Standard of care living donor - Mismatched Unrelated

Mismatched Unrelated PBSC donor

OTHER

Ossium HPC, Marrow

Cryopreserved deceased donor bone marrow

OTHER

Standard of care living donor - Haplo Related

Haplo Related PBSC donor

Sponsors & Collaborators

  • Ossium Health, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-01
Primary Completion
2029-03-31
Completion
2031-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07710781 on ClinicalTrials.gov